CD274 and non-small cell lung carcinoma: In patients with advanced non‐small‐cell lung cancer (NSCLC), treatment with programmed cell death‐1 (PD‐1) or programmed cell death‐ligand 1 (PD‐L1) inhibitors has become part of standard care.